These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15202012)
1. Molecular therapy versus standard treatment in allergy (Review). Grzela K; Lazarczyk M; Dziunycz P; Milewski L; Niderla J; Grzela T Int J Mol Med; 2004 Jul; 14(1):3-22. PubMed ID: 15202012 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. From allergen genes to new forms of allergy diagnosis and treatment. Vrtala S Allergy; 2008 Mar; 63(3):299-309. PubMed ID: 18269675 [TBL] [Abstract][Full Text] [Related]
4. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Chang TW; Wu PC; Hsu CL; Hung AF Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539 [TBL] [Abstract][Full Text] [Related]
5. Engineered recombinant ovomucoid third domain can modulate allergenic response in Balb/c mice model. Rupa P; Mine Y Biochem Biophys Res Commun; 2006 Apr; 342(3):710-7. PubMed ID: 16494843 [TBL] [Abstract][Full Text] [Related]
6. Relationships between specific serum IgE, cytokines and polymorphisms in the IL-4, IL-4Ralpha in patients with penicillins allergy. Qiao HL; Yang J; Zhang YW Allergy; 2005 Aug; 60(8):1053-9. PubMed ID: 15969687 [TBL] [Abstract][Full Text] [Related]
7. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Cosmi L; Santarlasci V; Angeli R; Liotta F; Maggi L; Frosali F; Rossi O; Falagiani P; Riva G; Romagnani S; Annunziato F; Maggi E Clin Exp Allergy; 2006 Mar; 36(3):261-72. PubMed ID: 16499636 [TBL] [Abstract][Full Text] [Related]
10. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280 [TBL] [Abstract][Full Text] [Related]
11. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Asturias JA; Ibarrola I; Arilla MC; Vidal C; Ferrer A; Gamboa PM; Viñuela JE; Sanz ML; Andreu C; Martínez A Clin Exp Allergy; 2009 Jul; 39(7):1088-98. PubMed ID: 19400901 [TBL] [Abstract][Full Text] [Related]
12. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. O'Malley BW; Li D; McQuone SJ; Ralston R Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147 [TBL] [Abstract][Full Text] [Related]
13. Scientific rationale for the Finnish Allergy Programme 2008-2018: emphasis on prevention and endorsing tolerance. von Hertzen LC; Savolainen J; Hannuksela M; Klaukka T; Lauerma A; Mäkelä MJ; Pekkanen J; Pietinalho A; Vaarala O; Valovirta E; Vartiainen E; Haahtela T Allergy; 2009 May; 64(5):678-701. PubMed ID: 19383025 [TBL] [Abstract][Full Text] [Related]
15. Genetically glycosylated ovomucoid third domain can modulate Immunoglobulin E antibody production and cytokine response in BALB/c mice. Rupa P; Nakamura S; Mine Y Clin Exp Allergy; 2007 Jun; 37(6):918-28. PubMed ID: 17517106 [TBL] [Abstract][Full Text] [Related]
16. Immunomodulation: the future cure for allergic diseases. Tsitoura DC; Tassios Y Ann N Y Acad Sci; 2006 Nov; 1088():100-15. PubMed ID: 17192559 [TBL] [Abstract][Full Text] [Related]